Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dopamine D3 receptor Ser9Gly polymorphism and risperidone response.

Hsien-Yuan Lane1, Shih-Kuan Hsu, Yi-Ching Liu

  • 1Department of Psychiatry and Medical Research, China Medical University Hospital, Taichung, Taiwan. hylane@pchome.com.tw

Journal of Clinical Psychopharmacology
|January 12, 2005
PubMed
Summary

The dopamine D3 receptor (DRD3) Ser9Gly polymorphism influences risperidone treatment response in schizophrenia patients, particularly for negative symptoms and social functioning. This genetic factor may guide personalized antipsychotic therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Superoxide dismutase and glutathione interact to determine cognitive outcome among people with subjective cognitive decline (SCD): a prospective study.

European archives of psychiatry and clinical neuroscience·2026
Same author

Machine learning-based integration of respiratory oscillometry and spirometry for predicting clinical outcomes in spinal muscular atrophy.

European journal of pediatrics·2026
Same author

Andrographolide Modulates Fibrogenic and Oxidative Stress Responses in Human Lung Fibroblasts.

The Kaohsiung journal of medical sciences·2026
Same author

Gender-specific effects of sodium benzoate on cognitive improvement in individuals with dementia: a meta-analysis of randomized controlled trials.

European archives of psychiatry and clinical neuroscience·2026
Same author

Sodium benzoate, a D-amino acids oxidase inhibitor, for the treatment of mild cognitive impairment: Pooled data from three randomized, double-blind, placebo-controlled trials.

Psychiatry and clinical neurosciences·2026
Same author

Both the PANSS cognitive component and MATRICS consensus cognitive domains are linked to functional outcome in patients with schizophrenia: A cross-sectional study.

Progress in neuro-psychopharmacology & biological psychiatry·2026

Area of Science:

  • Pharmacogenetics
  • Neuroscience
  • Psychiatry

Background:

  • Risperidone, an atypical antipsychotic, effectively treats schizophrenia's positive and negative symptoms.
  • Dopamine D3 receptor antagonism is a potential mechanism for risperidone's efficacy, especially in negative symptoms.
  • Genetic variations in the dopamine D3 receptor (DRD3) gene may modulate treatment response.

Purpose of the Study:

  • To investigate the impact of the DRD3 Ser9Gly polymorphism on risperidone response in schizophrenia patients.
  • To analyze the association between DRD3 genotypes and clinical outcomes, including negative symptoms and social functioning.
  • To control for nongenetic factors influencing treatment response.

Main Methods:

  • A cohort of 123 Han Chinese schizophrenia patients received risperidone monotherapy for up to 42 days.

Related Experiment Videos

  • Clinical assessments included the Positive and Negative Syndrome Scale and Nurses' Observation Scale for Inpatients Evaluation.
  • Generalized estimating equation methods were used to analyze the effects of the Ser9Gly polymorphism and covariates on clinical performance.

    • Main Results:

    • Patients with Ser9Ser or Ser9Gly genotypes showed significantly better response in negative symptoms compared to Gly9Gly (P = 0.0002 and 0.0092).
    • The Ser9Ser genotype was associated with improved social functioning compared to Gly9Gly (P = 0.0029).
    • The DRD3 Ser9Gly polymorphism did not significantly affect positive symptoms; male gender, fewer hospitalizations, and higher dosage predicted better response.

    Conclusions:

    • The DRD3 Ser9Gly polymorphism may influence risperidone's efficacy for negative symptoms and social functioning in schizophrenia.
    • Genetic variations, potentially in linkage disequilibrium with DRD3, could personalize risperidone treatment strategies.
    • Further research is warranted to elucidate the precise genetic underpinnings of risperidone response.